Syndax Pharmaceuticals (SNDX) vs Stoke Therapeutics (STOK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Syndax Pharmaceuticals (SNDX) has outperformed Stoke Therapeutics (STOK) over the past year, gaining 2.4% versus a loss of 21.5%. Over five years, STOK leads with a +1.8% price change compared with -9.1% for SNDX. Stoke Therapeutics is the larger company by market cap ($1.55 billion vs $1.51 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SNDX | STOK |
|---|---|---|
| Share price | $16.90 | $23.95 |
| Market cap | $1.51B | $1.55B |
| 1-day change | -0.76% | -1.40% |
| YTD return | -19.56% | -24.54% |
| 1-year return | +2.42% | -21.48% |
| 5-year return | -9.09% | +1.83% |
| EPS (TTM) | $-2.52 | $-3.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.59 | $40.22 |
| 52-week low | $12.99 | $20.32 |
| Distance from 52-week high | -33.96% | -40.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +122.19% | +93.99% |
| Average volume | 1.55M | 855.13K |
| Shares outstanding | 89.30M | 64.53M |
| Employees | 298 | 170 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SNDX has outperformed STOK by 23.9 percentage points over the past year.
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees
SNDX vs STOK FAQ
Which is bigger, Syndax Pharmaceuticals or Stoke Therapeutics?
Stoke Therapeutics (STOK) is larger, with a market capitalization of $1.55B compared with $1.51B for Syndax Pharmaceuticals (SNDX).
Which stock has performed better over the past year, SNDX or STOK?
SNDX returned +2.42% over the past 12 months, compared with -21.48% for STOK (price return, excluding dividends). Past performance does not predict future results.
Are Syndax Pharmaceuticals and Stoke Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.